BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 35075112)

  • 1. Galectin-1 confers resistance to doxorubicin in hepatocellular carcinoma cells through modulation of P-glycoprotein expression.
    Carabias P; Espelt MV; Bacigalupo ML; Rojas P; Sarrias L; Rubin A; Saffioti NA; Elola MT; Rossi JP; Wolfenstein-Todel C; Rabinovich GA; Troncoso MF
    Cell Death Dis; 2022 Jan; 13(1):79. PubMed ID: 35075112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sensitization of hepatocellular carcinoma cells towards doxorubicin and sorafenib is facilitated by glucosedependent alterations in reactive oxygen species, P-glycoprotein and DKK4.
    Chouhan S; Singh S; Athavale D; Ramteke P; Vanuopadath M; Nair BG; Nair SS; Bhat MK
    J Biosci; 2020; 45():. PubMed ID: 32713860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Galectin-1 Controls the Proliferation and Migration of Liver Sinusoidal Endothelial Cells and Their Interaction With Hepatocarcinoma Cells.
    Manzi M; Bacigalupo ML; Carabias P; Elola MT; Wolfenstein-Todel C; Rabinovich GA; Espelt MV; Troncoso MF
    J Cell Physiol; 2016 Jul; 231(7):1522-33. PubMed ID: 26551914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Galectin-1 triggers epithelial-mesenchymal transition in human hepatocellular carcinoma cells.
    Bacigalupo ML; Manzi M; Espelt MV; Gentilini LD; Compagno D; Laderach DJ; Wolfenstein-Todel C; Rabinovich GA; Troncoso MF
    J Cell Physiol; 2015 Jun; 230(6):1298-309. PubMed ID: 25469885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MiR-34a overexpression enhances the inhibitory effect of doxorubicin on HepG2 cells.
    Zheng SZ; Sun P; Wang JP; Liu Y; Gong W; Liu J
    World J Gastroenterol; 2019 Jun; 25(22):2752-2762. PubMed ID: 31235998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced cytotoxicity in doxorubicin-exposed HepG2 cells pretreated with menthol due to upregulation of P-glycoprotein.
    Nagai K; Fukuno S; Miura T; Uchino Y; Sehara N; Konishi H
    Pharmazie; 2020 Oct; 75(10):510-511. PubMed ID: 33305727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Connexin 32 affects doxorubicin resistance in hepatocellular carcinoma cells mediated by Src/FAK signaling pathway.
    Yu M; Zou Q; Wu X; Han G; Tong X
    Biomed Pharmacother; 2017 Nov; 95():1844-1852. PubMed ID: 28968929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Down-regulation of extracellular signal-regulated kinase 1/2 activity in P-glycoprotein-mediated multidrug resistant hepatocellular carcinoma cells.
    Yan F; Wang XM; Pan C; Ma QM
    World J Gastroenterol; 2009 Mar; 15(12):1443-51. PubMed ID: 19322916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53 and P-glycoprotein influence chemoresistance in hepatocellular carcinoma.
    Li S; Gao M; Li Z; Song L; Gao X; Han J; Wang F; Chen Y; Li W; Yang J
    Front Biosci (Elite Ed); 2018 Jun; 10(3):461-468. PubMed ID: 29772519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
    Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M
    J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TGF-β induced chemoresistance in liver cancer is modulated by xenobiotic nuclear receptor PXR.
    Bhagyaraj E; Ahuja N; Kumar S; Tiwari D; Gupta S; Nanduri R; Gupta P
    Cell Cycle; 2019 Dec; 18(24):3589-3602. PubMed ID: 31739702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delivery of miR-375 and doxorubicin hydrochloride by lipid-coated hollow mesoporous silica nanoparticles to overcome multiple drug resistance in hepatocellular carcinoma.
    Xue H; Yu Z; Liu Y; Yuan W; Yang T; You J; He X; Lee RJ; Li L; Xu C
    Int J Nanomedicine; 2017; 12():5271-5287. PubMed ID: 28769563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Galectin-1-mediated MET/AXL signaling enhances sorafenib resistance in hepatocellular carcinoma by escaping ferroptosis.
    Hsu TW; Su YH; Chen HA; Liao PH; Shen SC; Tsai KY; Wang TH; Chen A; Huang CY; Shibu MA; Wang WY; Shen SC
    Aging (Albany NY); 2023 Jul; 15(13):6503-6525. PubMed ID: 37433225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
    Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
    Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation.
    Lai SC; Su YT; Chi CC; Kuo YC; Lee KF; Wu YC; Lan PC; Yang MH; Chang TS; Huang YH
    J Exp Clin Cancer Res; 2019 Nov; 38(1):474. PubMed ID: 31771617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exosomal MiR-744 Inhibits Proliferation and Sorafenib Chemoresistance in Hepatocellular Carcinoma by Targeting PAX2.
    Wang G; Zhao W; Wang H; Qiu G; Jiang Z; Wei G; Li X
    Med Sci Monit; 2019 Sep; 25():7209-7217. PubMed ID: 31553714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization and resistance mechanisms of a 5-fluorouracil- resistant hepatocellular carcinoma cell line.
    Gu W; Fang FF; Li B; Cheng BB; Ling CQ
    Asian Pac J Cancer Prev; 2012; 13(9):4807-14. PubMed ID: 23167424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beneficial effect of cepharanthine on overcoming drug-resistance of hepatocellular carcinoma.
    Nakajima A; Yamamoto Y; Taura K; Hata K; Fukumoto M; Uchinami H; Yonezawa K; Yamaoka Y
    Int J Oncol; 2004 Mar; 24(3):635-45. PubMed ID: 14767548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SOX9 enhances sorafenib resistance through upregulating ABCG2 expression in hepatocellular carcinoma.
    Wang M; Wang Z; Zhi X; Ding W; Xiong J; Tao T; Yang Y; Zhang H; Zi X; Zhou W; Huang G
    Biomed Pharmacother; 2020 Sep; 129():110315. PubMed ID: 32554246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relevance of two genes in the multidrug resistance of hepatocellular carcinoma: in vivo and clinical studies.
    Sun Z; Zhao Z; Li G; Dong S; Huang Z; Ye L; Liang H; Qu J; Ai X; Zhang W; Chen X
    Tumori; 2010; 96(1):90-6. PubMed ID: 20437864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.